154 related articles for article (PubMed ID: 32096103)
1. Data Integrity in the Pharmaceutical Industry: Analysis of Inspections and Warning Letters Issued by the Bioresearch Monitoring Program Between Fiscal Years 2007-2018.
Rogers CA; Ahearn JD; Bartlett MG
Ther Innov Regul Sci; 2020 Sep; 54(5):1123-1133. PubMed ID: 32096103
[TBL] [Abstract][Full Text] [Related]
2. Analysis of warning letters issued by the US Food and Drug Administration to clinical investigators, institutional review boards and sponsors: a retrospective study.
Shetty YC; Saiyed AA
J Med Ethics; 2015 May; 41(5):398-403. PubMed ID: 24965716
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Analysis of Clinical Research Misconduct Using FDA-Issued Warning Letters and Clinical Investigator Inspection List From 2010 to 2014.
Romano CA; Nair S; Delphin ES
Anesth Analg; 2018 Mar; 126(3):976-982. PubMed ID: 29239950
[TBL] [Abstract][Full Text] [Related]
4. Research Misconduct in FDA-Regulated Clinical Trials: A Cross-sectional Analysis of Warning Letters and Disqualification Proceedings.
Garmendia CA; Bhansali N; Madhivanan P
Ther Innov Regul Sci; 2018 Sep; 52(5):592-605. PubMed ID: 29714564
[TBL] [Abstract][Full Text] [Related]
5. An FDA Analysis of Inspected Entities After Receiving Official Action Indicated Letters for Good Clinical Practice Violations.
Jung M; Swann RM; Anantha MS; Jamali F
Ther Innov Regul Sci; 2021 Sep; 55(5):907-917. PubMed ID: 34101151
[TBL] [Abstract][Full Text] [Related]
6. A study of warning letters issued to institutional review boards by the United States Food and Drug Administration.
Bramstedt KA; Kassimatis K
Clin Invest Med; 2004 Dec; 27(6):316-23. PubMed ID: 15675112
[TBL] [Abstract][Full Text] [Related]
7. A study of warning letters issued to clinical investigators by the United States Food and Drug Administration.
Bramstedt KA
Clin Invest Med; 2004 Jun; 27(3):129-34. PubMed ID: 15305804
[TBL] [Abstract][Full Text] [Related]
8. Over-the-Counter Drugs: Regulatory Analysis of Warning Letters Between Fiscal Years 2015-2019.
Bai HK; Ahearn JD; Bartlett MG
Ther Innov Regul Sci; 2021 Mar; 55(2):426-436. PubMed ID: 33095420
[TBL] [Abstract][Full Text] [Related]
9. Research Deviations in FDA-Regulated Clinical Trials: A Cross-Sectional Analysis of FDA Inspection Citations.
Garmendia CA; Epnere K; Bhansali N
Ther Innov Regul Sci; 2018 Sep; 52(5):579-591. PubMed ID: 29714561
[TBL] [Abstract][Full Text] [Related]
10. Analysis of FDA Warning Letters Issued to Indian Pharmaceutical and Medical Device Companies: A Retrospective Study.
Bablani S; Janodia MD
Ther Innov Regul Sci; 2020 Jul; 54(4):925-931. PubMed ID: 32557315
[TBL] [Abstract][Full Text] [Related]
11. An audit of US FDA warning letters issued to sponsors, institutional review boards and investigators over a six-year period.
Saxena U; Bose D; Saha S; Gogtay NJ; Thatte UM
Indian J Med Ethics; 2022; VII(2):108-113. PubMed ID: 35765256
[TBL] [Abstract][Full Text] [Related]
12. A study of warning letters issued to clinical investigators and institutional review boards by the United States Food and Drug Administration.
Gogtay NJ; Doshi BM; Kannan S; Thatte U
Indian J Med Ethics; 2011; 8(4):211-4. PubMed ID: 22106658
[TBL] [Abstract][Full Text] [Related]
13. FDA Warning Letters: A Retrospective Analysis of Letters Issued to Pharmaceutical Companies from 2010-2020.
Rathore AS; Li Y; Chhabra H; Lohiya A
J Pharm Innov; 2022 Aug; ():1-10. PubMed ID: 35992018
[TBL] [Abstract][Full Text] [Related]
14. Warning letters to sponsor-investigators at academic health centres - the regulatory "canaries in a coal mine".
O'Reilly EK; Blair Holbein ME; Berglund JP; Parrish AB; Roth MT; Burnett BK
Clin Invest Med; 2013 Dec; 36(6):E290-6. PubMed ID: 24309225
[TBL] [Abstract][Full Text] [Related]
15. Analysis of FDA Warning Letters Issued to Indian Pharmaceutical and Medical Device Companies: A Retrospective Study.
Bablani S; Janodia MD
Ther Innov Regul Sci; 2019 Nov; ():2168479019879380. PubMed ID: 31690096
[TBL] [Abstract][Full Text] [Related]
16. Raising suspicions with the Food and Drug Administration: detecting misconduct.
Hamrell MR
Sci Eng Ethics; 2010 Dec; 16(4):697-704. PubMed ID: 20842536
[TBL] [Abstract][Full Text] [Related]
17. A review of FDA warning letters and notices of violation issued for patient-reported outcomes promotional claims between 2006 and 2012.
Symonds T; Hackford C; Abraham L
Value Health; 2014 Jun; 17(4):433-7. PubMed ID: 24969004
[TBL] [Abstract][Full Text] [Related]
18. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.
Kim H
Int J Health Policy Manag; 2015 Aug; 4(12):813-21. PubMed ID: 26673465
[TBL] [Abstract][Full Text] [Related]
19. Trend Analysis of FDA Warning Letters Issued to Medical Products About Violations to Current Good Manufacturing Practices (CGMP) Between 2007 and 2014.
Wang L; Zheng H; Ren X; Sun H
Ther Innov Regul Sci; 2016 May; 50(3):312-318. PubMed ID: 30227064
[TBL] [Abstract][Full Text] [Related]
20. Data Integrity: History, Issues, and Remediation of Issues.
Rattan AK
PDA J Pharm Sci Technol; 2018; 72(2):105-116. PubMed ID: 29158286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]